The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-LOX 1 antibody (ab65864)
70 - 90% by HPLC.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions. - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer. - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent. - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised. - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
C-type lectin domain family 8 member A
Lectin like oxidized LDL receptor 1
Lectin like oxLDL receptor 1
Lectin type oxidized LDL receptor 1
Lectin-like oxidized LDL receptor 1
Lectin-like oxLDL receptor 1
Lectin-type oxidized LDL receptor 1
low density lipoprotein oxidized, receptor 1
Ox LDL receptor 1
Ox-LDL receptor 1
Oxidised low density lipoprotein (lectin like) receptor 1
Oxidized low density lipoprotein receptor 1
Oxidized low density lipoprotein receptor 1 soluble form
Oxidized low-density lipoprotein receptor 1
Scavenger receptor class E, member 1
Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Expressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver and brain, aortic intima, bone marrow, spinal cord and substantia nigra. Also expressed at the surface of dendritic cells. Widely expressed at intermediate and low level.
Involvement in disease
Note=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility. Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.
Contains 1 C-type lectin domain.
The cytoplasmic region is required for subcellular sorting on the cell surface. The C-type lectin domain mediates the recognition and binding of oxLDL.
The intrachain disulfide-bonds prevent N-glycosylation at some sites. N-glycosylated.
Cell membrane. Secreted. A secreted form also exists.